312 related articles for article (PubMed ID: 26269605)
21. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.
Bertolini G; Cancila V; Milione M; Lo Russo G; Fortunato O; Zaffaroni N; Tortoreto M; Centonze G; Chiodoni C; Facchinetti F; Pollaci G; Taiè G; Giovinazzo F; Moro M; Camisaschi C; De Toma A; D'Alterio C; Pastorino U; Tripodo C; Scala S; Sozzi G; Roz L
Mol Ther; 2021 Oct; 29(10):2963-2978. PubMed ID: 34023505
[TBL] [Abstract][Full Text] [Related]
22. Adenosine A2A receptor activation reduces brain metastasis via SDF-1/CXCR4 axis and protecting blood-brain barrier.
Chen L; Li L; Zhou C; Chen X; Cao Y
Mol Carcinog; 2020 Apr; 59(4):390-398. PubMed ID: 32037613
[TBL] [Abstract][Full Text] [Related]
23. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
24. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
25. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers.
Ananthula S; Sinha A; El Gassim M; Batth S; Marshall GD; Gardner LH; Shimizu Y; ElShamy WM
Oncotarget; 2016 Apr; 7(15):20869-89. PubMed ID: 26989079
[TBL] [Abstract][Full Text] [Related]
26. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
[TBL] [Abstract][Full Text] [Related]
27. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
[TBL] [Abstract][Full Text] [Related]
28. ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling.
Masuda T; Endo M; Yamamoto Y; Odagiri H; Kadomatsu T; Nakamura T; Tanoue H; Ito H; Yugami M; Miyata K; Morinaga J; Horiguchi H; Motokawa I; Terada K; Morioka MS; Manabe I; Iwase H; Mizuta H; Oike Y
Sci Rep; 2015 Mar; 5():9170. PubMed ID: 25773070
[TBL] [Abstract][Full Text] [Related]
29. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
30. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
34. Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells.
Sirohi VK; Popli P; Sankhwar P; Kaushal JB; Gupta K; Manohar M; Dwivedi A
J Nutr Biochem; 2017 Jun; 44():60-70. PubMed ID: 28402926
[TBL] [Abstract][Full Text] [Related]
35. Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model.
Qin G; Chen Y; Li H; Xu S; Li Y; Sun J; Rao W; Chen C; Du M; He K; Ye Y
Mol Med Rep; 2016 Jul; 14(1):57-68. PubMed ID: 27177128
[TBL] [Abstract][Full Text] [Related]
36. Peptide density targets and impedes triple negative breast cancer metastasis.
Liu D; Guo P; McCarthy C; Wang B; Tao Y; Auguste D
Nat Commun; 2018 Jul; 9(1):2612. PubMed ID: 29973594
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo.
Ma N; Pang H; Shen W; Zhang F; Cui Z; Wang J; Wang J; Liu L; Zhang H
Int J Mol Med; 2015 Feb; 35(2):425-32. PubMed ID: 25504108
[TBL] [Abstract][Full Text] [Related]
38. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
Liang DH; Choi DS; Ensor JE; Kaipparettu BA; Bass BL; Chang JC
Cancer Lett; 2016 Jul; 376(2):249-58. PubMed ID: 27060208
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
[TBL] [Abstract][Full Text] [Related]
40. [Effect of stromal cell-derived factor-1 and its receptor CXCR4 on liver metastasis of human colon cancer].
Ding YL; Fu QY; Tang SF; Zhang JL; Li ZY; Li ZT
Zhonghua Wai Ke Za Zhi; 2009 Feb; 47(3):210-3. PubMed ID: 19563077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
